source
- LifeMine Therapeutics secures $263 million in dual venture rounds to advance organ transplant aftercare drugLifeMine Therapeutics announced it has raised a total of $263 million through a $75 million Series D and an $188 million Series F round, opting for private financing rather than an IPO. The capita…
- Braveheart Bio targets $382 million IPO to fund cardiac drug developmentBraveheart Bio announced an upsized initial public offering on the Nasdaq, aiming to raise about $382.5 million. The company will sell 21.2 million shares at $18 each under the ticker BRVE. The pr…